Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a0d387e00ca94a52804049c00815d14 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
filingDate |
2018-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9cd5f2af8a958cde365023c122c1827 |
publicationDate |
2019-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019032437-A1 |
titleOfInvention |
LIPOSOMAL TAXANES FOR TREATMENT OF CPPC |
abstract |
The invention provides methods of treating small cell lung cancer (SCLC), which may or may not respond to first-line therapy or progress after discontinuation of first-line chemotherapy. Some methods include administering a composition that comprises a form of protein stabilized docetaxel, optionally in conjunction with a supportive care regimen. |
priorityDate |
2017-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |